Journal
ANTIVIRAL RESEARCH
Volume 122, Issue -, Pages 12-19Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2015.07.010
Keywords
Nucleoside analogs; Dengue virus; Antiviral therapy; Monophosphate prodrug
Categories
Ask authors/readers for more resources
Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available